INTerpath-014: what one clinician is saying
intismeran autogene plus MK-3475A; intismeran autogene in resected high-risk stage I non-small cell lung cancer · NCT07513376 ↗ · Phase 3 · Merck Sharp & Dohme LLC
For INTerpath-014, a speaker regards benefit without pembrolizumab as unresolved because earlier melanoma signals arose with combination treatment, while another asserts intismeran requires pembrolizumab. Their clinical roles are not established, and the commentary offers no assessment of the trial’s benefit or tolerability.
Created with AI · how we check it
- edition 1
- commentary checked Nov 22, 2026
- 79 verified statements
10 findings, and what sits behind each
01. Vaccine monotherapy: what speakers say
No named clinician · accounts and unnamed speakers · 7 statements from 1 speaker in 5 sources · 6 passages
Limitations recorded: 2.
Draws on: The comparison, Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C, Population and setting.
02. INTerpath-014: some speakers see design information, not a lung efficacy readout
No named clinician · accounts and unnamed speakers · 8 statements in 7 sources · 7 passages
Limitations recorded: 3.
Draws on: Design and conduct, Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C, Population and setting.
03. High-risk stage I NSCLC: why speakers welcome testing treatment earlier
1 of the report's 1 cited clinicians · 4 statements from 2 speakers in 2 sources · 2 passages
Limitations recorded: 3.
Draws on: Population and setting, Design and conduct.
04. Intismeran supply: speakers see limits, but one accepts the launch case
No named clinician · accounts and unnamed speakers · 9 statements in 4 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 5.
Draws on: Population and setting.
05. SC use: a speaker cites IV time, and one sees franchise value if it works
No named clinician · accounts and unnamed speakers · 4 statements in 3 sources · 3 passages
Limitations recorded: 3.
Draws on: The comparison.
06. Trial access: what speakers say
No named clinician · accounts and unnamed speakers · 15 statements in 2 sources, all podcasts or videos · 4 passages
Limitations recorded: 4.
Draws on: Population and setting.
07. Colorectal vaccine data: speakers limit extrapolation, but stress PD-1 context
No named clinician · accounts and unnamed speakers · 8 statements in 2 sources · 3 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C, The comparison, Population and setting.
08. Commercial expectations: what speakers say
No named clinician · accounts and unnamed speakers · 10 statements from 1 speaker in 6 sources · 6 passages
Limitations recorded: 3.
Draws on: Design and conduct, The comparison.
Beyond the trial population
09. Lung vaccines: why a speaker expects no edge over neoadjuvant checkpoint inhibition
No named clinician · accounts and unnamed speakers · 2 statements in 2 sources · 2 passages
Limitations recorded: 2.
10. Melanoma: most speakers need lung data; most see conditional trial support
No named clinician · accounts and unnamed speakers · 20 statements in 5 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
No named clinician · accounts and unnamed speakers
Vaccine monotherapy: what speakers say
7 statements from 1 speaker in 5 sources
- 7
- statements
- 6
- passages
- 5
- sources
- 1
- speaker
What the statements areViews 3Questions and uncertainty 0Clinical experience 0Comparisons 2Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 8Giving context 0Recorded with the findingLimitations: 2
5 posts and articles
Draws on: The comparison, Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C, Population and setting.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 10 findings and 20 of the 79 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (6)
BICR, blinded independent central review; DFS, disease-free survival; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; NSCLC, non-small cell lung cancer.
The full INTerpath-014 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 22commentary sources screened
- 18sources cited by verified statements
- 3named in screened sources
- 3speakers cited in the report
- 2cited speakers with a verified identity
1 cited clinician, a speaker with a confirmed clinical role, of them 1 physician. By role and specialty:
- 1 physician, specialty not confirmed
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 79verified statements, each linked to its source
- 1of them from speakers with a confirmed clinical role
- 10findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 79 | Paid |
| Who said each statement: the cited speakers | 3 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 1 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 2 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 18 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
10 discussed · 2 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C | 4 | 4 |
| Secondary endpointsno commentary found | 0 | 0 |
| Population and setting | 12 | 9 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 9 | 6 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conduct | 10 | 8 |
| Postoperative manufacturing, tissue and timing | 10 | 4 |
| Administration route and workflow | 4 | 3 |
| Research access, eligibility review and patient support | 15 | 3 |
| Cross-cancer expectations, mutation burden and vaccine-only uncertainty | 28 | 6 |
| Commercial expectations and economic uncertainty | 8 | 6 |
| Comparison with neoadjuvant checkpoint blockade | 2 | 2 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
79 verified statements from 18 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 20 statements · 25% | ||||
| YouTube | 20 | 2 | 2 | |
| Posts · 59 statements · 75% | ||||
| X threads | 56 | 15 | 19 | |
| LinkedIn posts | 3 | 1 | 1 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 11 / quarter
- Screened window
- Apr 27, 2026 → Oct 26, 2026
- Cited window
- Apr 27, 2026 → Oct 26, 2026
- Retrieved
- Nov 22, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
- Registry
- NCT07513376
- Study IDs
- V940-014 · U1111-1323-9950 (UTN) · 2025-522643-18-00 (EU CT) · jRCT2021260028 (Japan Registry of Clinical Trials (jRCT))
- Sponsor
- Merck Sharp & Dohme LLC
- Collaborators
- ModernaTX, Inc.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 876 estimated
- Registered
- 2026-04-07
- Start
- 2026-05-04 actual
- Primary completion
- 2034-08-22 estimated
- Primary endpoint
- Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C
- Interventions
- 3 registered
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, capacity and access barriers in resectable lung cancer; a view on actual vaccine receipt and time to dosing when evaluating adjuvant vaccination.
- 17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 43 sources about other trials or topics are not included.
- The sources reviewed for this edition are selected public discussions, not a representative sample of HCP views. Repeated posts by one account do not establish independent agreement.
Show all 11 known gaps +Fewer −
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The exact trial protocol and a results publication for NCT07513376 were not found in the reviewed materials. The cited congress statements describe trial design rather than efficacy results and do not provide an INTerpath-014 safety assessment.
- Exact product labels were not available for independent assessment of approval-scope statements. Access, pricing and regulatory expectations remain attributed, time-specific accounts.
- Melanoma subgroup findings and comparisons with another vaccine in colorectal cancer are exploratory or cross-trial context, not evidence of benefit or harm in INTerpath-014.
- Source accounts differ on study-start timing. The August 2034 primary-completion date is an estimate, and an account's eight-year readout interpretation is not a guaranteed timetable.
- The neoadjuvant comparison does not include a full account of the connected perioperative-immunotherapy evidence or concerns about testing, capacity and access; it should not be read as a comprehensive comparison.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 2 fixes (names, counts, tags, text)
None of these changed a statement, finding or source.
- Nov 22, 2026 UTCThe trial's name is spelled as its investigators write it, “INTerpath-014” (NCT07513376), outside quotations (was “INTERpath”, “INTERpath-014”).
- Nov 22, 2026 UTCtaxonomy mapping corrected
Last checked for new commentary Nov 22, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. INTerpath-014 (NCT07513376): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/interpath-014-nct07513376
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "INTerpath-014" (NCT07513376), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "interpath-014-nct07513376". If you cannot make requests, read https://www.erudio.com/reports/interpath-014-nct07513376.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07513376", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07513376 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/interpath-014-nct07513376.json
curl https://www.erudio.com/reports/interpath-014-nct07513376.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "interpath-014-nct07513376" })release 9bd4cd18fd851b00956dcad585ec8613464af354451493d2a76c50bee115fa79
Questions
How much does the INTerpath-014 report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the INTerpath-014 report cover?
79 statements from 18 sources (2 videos, 16 posts), 1 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the INTerpath-014 report?
Its preview, yes: get_report_card({ "slug": "interpath-014-nct07513376" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the INTerpath-014 report?
Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.